董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vipin Garg | 男 | Chief Executive Officer, President and Director | 59 | 108.47万美元 | 未持股 | 2017-04-28 |
| Alan Heller | 男 | Chairman of the board | 63 | 13.83万美元 | 未持股 | 2017-04-28 |
| Greg Robitaille | 男 | Director | 53 | 12.70万美元 | 未持股 | 2017-04-28 |
| Bryant Fong | 男 | Director | 44 | 12.20万美元 | 未持股 | 2017-04-28 |
| Paul Edick | 男 | Director | 61 | 12.20万美元 | 未持股 | 2017-04-28 |
| Beth Hecht | 女 | Director | 53 | 11.33万美元 | 未持股 | 2017-04-28 |
| John Schmid | 男 | Director | 54 | 12.83万美元 | 未持股 | 2017-04-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vipin Garg | 男 | Chief Executive Officer, President and Director | 59 | 108.47万美元 | 未持股 | 2017-04-28 |
| Richard Eisenstadt | 男 | Chief Financial Officer | 58 | 67.77万美元 | 未持股 | 2017-04-28 |
| Thomas McDonnell | 男 | Chief Commercial Officer | 45 | 127.95万美元 | 未持股 | 2017-04-28 |
| Dorothy Engelking | 女 | Vice President of Regulatory Affairs | 56 | 未披露 | 未持股 | 2017-04-28 |
| Juergen A. Martens | 男 | Chief Technology and Operations Officer | 61 | 120.64万美元 | 未持股 | 2017-04-28 |
董事简历
中英对照 | 中文 | 英文- Vipin Garg
-
Vipin Garg担任公司的首席执行官，2013年10月起担任董事会成员，2014年7月被任命为总裁。在加入公司之前，Garg博士担任Tranzyme股份有限公司（Tranzyme Inc.，现在的Ocera Therapeutics股份有限公司（Ocera Therapeutics, Inc.）NASDAQ： OCRX）的总裁、首席执行官和董事（2001年9月-2013年7月）。Garg博士也担任运营和业务拓展副总裁，随后担任Apex Bioscience股份有限公司（Apex Bioscience, Inc.）的运营总监（1994-2000年）；担任DNX Bio-Therapeutics股份有限公司（DNX Bio-Therapeutics, Inc.）的开发副总裁（1992-1994年）；担任Sepracor股份有限公司（Sepracor, Inc.，现在的Dainippon Sumitomo Pharma）的技术服务和营销董事（1989-1992年）；担任Bio-Response股份有限公司（Bio-Response Inc.）的合同服务经理（1986-1989年）。Garg博士也担任北卡罗来纳生物技术中心（North Carolina Biotechnology Center）董事会成员和CED（前身是创业发展委员会）的执行委员会工作，还是卡罗莱纳地区安永年度企业家奖（Ernst & Young Entrepreneur of the Year Award for the Carolinas Region）获得者。Garg博士拥有澳大利亚阿德雷德大学（University of Adelaide, Australia）生物技术博士学位、印度新德里印度农业研究所（Indian Agricultural Research Institute in New Delhi, India）硕士学位和印度密拉特大学（Meerut University, India）学士学位。
Vipin Garg has served as our Chief Executive Officer and a member of our board of directors since October 2013 and was named our President in July 2014. Prior to joining us, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme, Inc., now Ocera Therapeutics, Inc. NASDAQ: OCRX from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000 as Vice President of Development at DNX Bio-Therapeutics, Inc. from 1992 to 1994 as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992 and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst & Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India. - Vipin Garg担任公司的首席执行官，2013年10月起担任董事会成员，2014年7月被任命为总裁。在加入公司之前，Garg博士担任Tranzyme股份有限公司（Tranzyme Inc.，现在的Ocera Therapeutics股份有限公司（Ocera Therapeutics, Inc.）NASDAQ： OCRX）的总裁、首席执行官和董事（2001年9月-2013年7月）。Garg博士也担任运营和业务拓展副总裁，随后担任Apex Bioscience股份有限公司（Apex Bioscience, Inc.）的运营总监（1994-2000年）；担任DNX Bio-Therapeutics股份有限公司（DNX Bio-Therapeutics, Inc.）的开发副总裁（1992-1994年）；担任Sepracor股份有限公司（Sepracor, Inc.，现在的Dainippon Sumitomo Pharma）的技术服务和营销董事（1989-1992年）；担任Bio-Response股份有限公司（Bio-Response Inc.）的合同服务经理（1986-1989年）。Garg博士也担任北卡罗来纳生物技术中心（North Carolina Biotechnology Center）董事会成员和CED（前身是创业发展委员会）的执行委员会工作，还是卡罗莱纳地区安永年度企业家奖（Ernst & Young Entrepreneur of the Year Award for the Carolinas Region）获得者。Garg博士拥有澳大利亚阿德雷德大学（University of Adelaide, Australia）生物技术博士学位、印度新德里印度农业研究所（Indian Agricultural Research Institute in New Delhi, India）硕士学位和印度密拉特大学（Meerut University, India）学士学位。
- Vipin Garg has served as our Chief Executive Officer and a member of our board of directors since October 2013 and was named our President in July 2014. Prior to joining us, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme, Inc., now Ocera Therapeutics, Inc. NASDAQ: OCRX from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000 as Vice President of Development at DNX Bio-Therapeutics, Inc. from 1992 to 1994 as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992 and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst & Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India.
- Alan Heller
-
Alan Heller自2009年6月担任公司董事长。Heller先生自2006年1月起在Water Street Healthcare Partners有限责任公司（Water Street Healthcare Partners, LLC）担任运营合伙人。他是American Pharmaceutical Partners的总裁和首席执行官（2004年10月-2005年5月），先前是Baxter International的全球肾手术总裁（2000年9月-2004年1月）。早期，Heller先生担任Searle Operations的总裁（在和Pharmacia 公司（Pharmacia Corporation）整合时）。他目前担任私人拥有的公司Celerity Pharmaceuticals股份有限公司（Celerity Pharmaceuticals, Inc.）和Custopharm股份有限公司（Custopharm, Inc.）的董事长，也是BioClinica股份有限公司（BioClinica, Inc. NASDAQ： BIOC）的董事会成员。Heller先生拥有德尔堡大学（DePaul University）工商管理硕士学位和芝加哥伊利诺伊大学（University of Illinois, Chicago）学士学位。
Alan Heller has served as Chairman of our board of directors since June 2009. Mr. Heller has been an Operating Partner at Water Street Healthcare Partners, LLC, since January 2006. Mr. Heller was President and CEO of American Pharmaceutical Partners from October 2004 until November 2005 and prior to that was Corporate Vice President and President Global Renal at Baxter International from September 2000 until January 2004. Earlier, Mr. Heller served as President of Searle Operations at the time of its integration with Pharmacia Corporation. He currently serves as Chairman of the boards of directors of privately-held Capstone Development, Inc., Custopharm, Inc. and The Access Group. Mr. Heller holds an M.B.A. from DePaul University and a B.S. from the University of Illinois, Chicago. - Alan Heller自2009年6月担任公司董事长。Heller先生自2006年1月起在Water Street Healthcare Partners有限责任公司（Water Street Healthcare Partners, LLC）担任运营合伙人。他是American Pharmaceutical Partners的总裁和首席执行官（2004年10月-2005年5月），先前是Baxter International的全球肾手术总裁（2000年9月-2004年1月）。早期，Heller先生担任Searle Operations的总裁（在和Pharmacia 公司（Pharmacia Corporation）整合时）。他目前担任私人拥有的公司Celerity Pharmaceuticals股份有限公司（Celerity Pharmaceuticals, Inc.）和Custopharm股份有限公司（Custopharm, Inc.）的董事长，也是BioClinica股份有限公司（BioClinica, Inc. NASDAQ： BIOC）的董事会成员。Heller先生拥有德尔堡大学（DePaul University）工商管理硕士学位和芝加哥伊利诺伊大学（University of Illinois, Chicago）学士学位。
- Alan Heller has served as Chairman of our board of directors since June 2009. Mr. Heller has been an Operating Partner at Water Street Healthcare Partners, LLC, since January 2006. Mr. Heller was President and CEO of American Pharmaceutical Partners from October 2004 until November 2005 and prior to that was Corporate Vice President and President Global Renal at Baxter International from September 2000 until January 2004. Earlier, Mr. Heller served as President of Searle Operations at the time of its integration with Pharmacia Corporation. He currently serves as Chairman of the boards of directors of privately-held Capstone Development, Inc., Custopharm, Inc. and The Access Group. Mr. Heller holds an M.B.A. from DePaul University and a B.S. from the University of Illinois, Chicago.
- Greg Robitaille
-
Greg Robitaille自2009年6月担任公司董事会成员。自2011年7月起 Robitaille先生管理Water Street Healthcare Partners的公司发展活动。2009年4月-2011年7月，Robitaille先生担任Sarnova 有限责任公司（Sarnova LLC，Water Street Healthcare Partners的投资公司）的公司发展执行副总裁。Robitaille先生拥有汉弥尔顿林肯学院（Hamilton College）学士学位和哥伦比亚大学（Columbia University）工商管理硕士学位。
Greg Robitaille has served on our board of directors since June 2009. Since July 2011 Mr. Robitaille has managed Corporate Development activities at Water Street Healthcare Partners. Mr. Robitaille holds a B.A. from Hamilton College and an M.B.A. from Columbia University. - Greg Robitaille自2009年6月担任公司董事会成员。自2011年7月起 Robitaille先生管理Water Street Healthcare Partners的公司发展活动。2009年4月-2011年7月，Robitaille先生担任Sarnova 有限责任公司（Sarnova LLC，Water Street Healthcare Partners的投资公司）的公司发展执行副总裁。Robitaille先生拥有汉弥尔顿林肯学院（Hamilton College）学士学位和哥伦比亚大学（Columbia University）工商管理硕士学位。
- Greg Robitaille has served on our board of directors since June 2009. Since July 2011 Mr. Robitaille has managed Corporate Development activities at Water Street Healthcare Partners. Mr. Robitaille holds a B.A. from Hamilton College and an M.B.A. from Columbia University.
- Bryant Fong
-
Bryant Fong自2009年6月起在公司董事会工作。2013年10月他担任Biomark Capital有限责任合伙公司（Biomark Capital, LLP，一家生命科学风险资本基金）的创立一般合伙人。在加入Biomark Capital之前，Fong先生是Burrill & 公司（Burrill & Company）的经营董事（1998-2013年）。Fong先生拥有加州大学伯克利分校（University of California at Berkeley）生物化学学士学位。Fong先生目前在几家生命科学公司包括ADMA Biologics NASDAQ： ADMA董事会工作，担任JHL Biotech、 Biozeus和 i2Dx的审计和薪酬委员会工作。
Bryant Fong has served on our board of directors since June 2009. Since October 2013 he has served as founding General Partner at Biomark Capital, LLP, a life sciences venture capital fund. Prior to Biomark Capital, Mr. Fong was a Managing Director at Burrill & Company, from 1998 to 2013. Mr. Fong received his B.A. in Biochemistry from the University of California at Berkeley. Mr. Fong currently serves on the boards of several life science companies including ADMA Biologics NASDAQ: ADMA, where he serves on the audit and compensation committees, JHL Biotech, Biozeus and i2Dx. - Bryant Fong自2009年6月起在公司董事会工作。2013年10月他担任Biomark Capital有限责任合伙公司（Biomark Capital, LLP，一家生命科学风险资本基金）的创立一般合伙人。在加入Biomark Capital之前，Fong先生是Burrill & 公司（Burrill & Company）的经营董事（1998-2013年）。Fong先生拥有加州大学伯克利分校（University of California at Berkeley）生物化学学士学位。Fong先生目前在几家生命科学公司包括ADMA Biologics NASDAQ： ADMA董事会工作，担任JHL Biotech、 Biozeus和 i2Dx的审计和薪酬委员会工作。
- Bryant Fong has served on our board of directors since June 2009. Since October 2013 he has served as founding General Partner at Biomark Capital, LLP, a life sciences venture capital fund. Prior to Biomark Capital, Mr. Fong was a Managing Director at Burrill & Company, from 1998 to 2013. Mr. Fong received his B.A. in Biochemistry from the University of California at Berkeley. Mr. Fong currently serves on the boards of several life science companies including ADMA Biologics NASDAQ: ADMA, where he serves on the audit and compensation committees, JHL Biotech, Biozeus and i2Dx.
- Paul Edick
-
Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006. - Paul Edick自2015年6月起在公司董事会工作。他目前是3G Advisors有限责任公司（3G Advisors, LLC，医药，医疗保健和医疗保健投资者团体的顾问公司，2007年创立）的经营合伙人。2010年7月-2014年11月Edick先生是Durata Therapeutics的首席执行官，2014年11月和Actavis plc NYSE： ACT合并。在那之前，Edick先生是Ganic Pharmaceuticals的首席执行官（2008-2010年）；MedPointe Healthcare 股份有限公司（MedPointe Healthcare Inc.）的首席执行官（2006-2008年）；MedPointe的药学运营总裁（2002-2006年）。Edick先生在NewLink Genetics股份有限公司（NewLink Genetics Inc. （NASDAQ： NLNK））和Circassia Ltd. （LSE： CIR.L）董事会工作（2011年起）。他拥有纽约克林顿汉弥尔顿林肯学院（Hamilton College in Clinton, NY）心理学学士学位。
- Paul Edick has served as Xeris Pharmaceuticals, Inc. Chief Executive Officer since May 2021 in connection with the Strongbridge acquisition. Mr. Edick joined Xeris Pharmaceuticals, Inc. in January 2017 as President and Chief Executive Officer and was appointed as Chairman in June 2018. As of August 2020 Mr. Edick relinquished the President title he held at Xeris Pharmaceuticals, Inc. Previously, Mr. Edick was a founding partner of 3G Advisors, a consultancy firm to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014 Mr. Edick was the chief executive officer of Durata Therapeutics, Inc., a biopharmaceutical company, prior to its acquisition in November 2014. Prior to that, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from 2008 to 2010. Before that, from 2006 to 2008 Mr. Edick was chief executive officer of MedPointe Healthcare, Inc., a pharmaceutical company, and served as its president of pharmaceutical operations from 2002 to 2006.
- Beth Hecht
-
Beth Hecht， 她任职于Xeris Biopharma Holdings, Inc.董事会（2015年9月以来）。2012年10月以来，她曾担任Auven Therapeutics（全球私人股本公司，收购和开发医药产品，并解决未满足的医疗需求）的董事总经理兼首席法务和行政官。从2013年11月到2014年11月，她也曾担任Durata Therapeutics（于2014年11月与Actavis plc合并）的公司秘书、法务和合规顾问。此前，她曾担任the Sun Products Corporation的高级副总裁、总法律顾问和公司秘书（2009年3月至2012年9月），此前曾担任MedPointe Inc的执行副总裁兼总法律顾问。她持有Harvard Law School的法学博士学位，以及Amherst College的学士学位。
Beth Hecht has served as Xeris Pharmaceuticals, Inc. Chief Legal Officer and Corporate Secretary since October 2021 in connection with the Strongbridge acquisition. Ms. Hecht joined Xeris Pharmaceuticals, Inc. in January 2018 as the Senior Vice President, General Counsel and Corporate Secretary. Ms. Hecht has over twenty-five years of experience as a corporate executive in the life sciences industry, most recently serving from 2012 to 2018 as managing director and chief legal and administrative officer of Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm from 2012 to 2018. From November 2013 through November 2014 Ms. Hecht also served as corporate secretary and legal and compliance advisor at Durata Therapeutics, a biopharmaceutical company. Prior to that, she was senior vice president, general counsel and corporate secretary at the Sun Products Corporation from March 2009 through September 2012 and prior to that executive vice president and general counsel of MedPointe Healthcare, Inc., a pharmaceutical company. Since March 2021 Ms. Hecht has served on the board of directors of Iterum Therapeutics plc, a clinical stage pharmaceutical company, where she serves on the audit and compensation committees. Additionally, from September 2015 through March 2021 she served on the board of directors for Neos Therapeutics, Inc., a pharmaceutical company, where she chaired the nominating and corporate governance committee. Neos Therapeutics was acquired by Aytu Biopharma Inc. in March 2021. Ms. Hecht received a J.D. from Harvard Law School and a B.A. from Amherst College. - Beth Hecht， 她任职于Xeris Biopharma Holdings, Inc.董事会（2015年9月以来）。2012年10月以来，她曾担任Auven Therapeutics（全球私人股本公司，收购和开发医药产品，并解决未满足的医疗需求）的董事总经理兼首席法务和行政官。从2013年11月到2014年11月，她也曾担任Durata Therapeutics（于2014年11月与Actavis plc合并）的公司秘书、法务和合规顾问。此前，她曾担任the Sun Products Corporation的高级副总裁、总法律顾问和公司秘书（2009年3月至2012年9月），此前曾担任MedPointe Inc的执行副总裁兼总法律顾问。她持有Harvard Law School的法学博士学位，以及Amherst College的学士学位。
- Beth Hecht has served as Xeris Pharmaceuticals, Inc. Chief Legal Officer and Corporate Secretary since October 2021 in connection with the Strongbridge acquisition. Ms. Hecht joined Xeris Pharmaceuticals, Inc. in January 2018 as the Senior Vice President, General Counsel and Corporate Secretary. Ms. Hecht has over twenty-five years of experience as a corporate executive in the life sciences industry, most recently serving from 2012 to 2018 as managing director and chief legal and administrative officer of Auven Therapeutics, a global biotechnology and pharmaceutical private equity firm from 2012 to 2018. From November 2013 through November 2014 Ms. Hecht also served as corporate secretary and legal and compliance advisor at Durata Therapeutics, a biopharmaceutical company. Prior to that, she was senior vice president, general counsel and corporate secretary at the Sun Products Corporation from March 2009 through September 2012 and prior to that executive vice president and general counsel of MedPointe Healthcare, Inc., a pharmaceutical company. Since March 2021 Ms. Hecht has served on the board of directors of Iterum Therapeutics plc, a clinical stage pharmaceutical company, where she serves on the audit and compensation committees. Additionally, from September 2015 through March 2021 she served on the board of directors for Neos Therapeutics, Inc., a pharmaceutical company, where she chaired the nominating and corporate governance committee. Neos Therapeutics was acquired by Aytu Biopharma Inc. in March 2021. Ms. Hecht received a J.D. from Harvard Law School and a B.A. from Amherst College.
- John Schmid
-
John Schmid于2013年9月担任Moonlake Immunotherapeutics。的首席财务官。在加入Moonlake Immunotherapeutics。之前，他创立了Trius Therapeutics，一家上市生物制药公司，在那里他从2004年6月担任首席财务官，直到2013年9月与Cubist Pharmaceuticals合并。加入Trius Therapeutics之前，从1998年到2003年他在GeneFormatics担任首席财务官，一家私营生物技术公司。从1995年到1998年，在Endonetics公司工作，一家私人医疗设备公司。他目前担任Speak公司的董事会主席，a speakers bureau于1989年在他帮助下创立。他拥有卫斯理大学经济学学士和圣地亚哥大学的MBA。
John Schmid has served as a Director since January 2026. Mr. Schmid served on the board of directors of Helix I until the completion of its business combination with MoonLake, and of Helix II until its completion of its business combination with BBOT. Mr. Schmid currently serves as a member of the board of directors of AnaptysBio, Inc., Bright Peak Therapeutics and Design Therapeutics, all pharmaceutical companies, and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. He also previously served as a member of the board of directors of Poseida Therapeutics, Inc., Xeris Pharmaceuticals, Inc. and Blacksmith Medicines, Inc. (f/k/a Forge Therapeutics, Inc.). Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from 2013 until its sale to Teva Pharmaceuticals, Inc. in 2015. Prior to Auspex Pharmaceuticals, Inc., he co founded Trius Therapeutics, Inc. (formerly Nasdaq:TSRX), where he served as Chief Financial Officer from 2004 until its merger with Cubist Pharmaceuticals, Inc. in 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. Mr. Schmid holds a Bachelor's degree in Economics from Wesleyan University and a Master of Business Administration degree from the University of San Diego. - John Schmid于2013年9月担任Moonlake Immunotherapeutics。的首席财务官。在加入Moonlake Immunotherapeutics。之前，他创立了Trius Therapeutics，一家上市生物制药公司，在那里他从2004年6月担任首席财务官，直到2013年9月与Cubist Pharmaceuticals合并。加入Trius Therapeutics之前，从1998年到2003年他在GeneFormatics担任首席财务官，一家私营生物技术公司。从1995年到1998年，在Endonetics公司工作，一家私人医疗设备公司。他目前担任Speak公司的董事会主席，a speakers bureau于1989年在他帮助下创立。他拥有卫斯理大学经济学学士和圣地亚哥大学的MBA。
- John Schmid has served as a Director since January 2026. Mr. Schmid served on the board of directors of Helix I until the completion of its business combination with MoonLake, and of Helix II until its completion of its business combination with BBOT. Mr. Schmid currently serves as a member of the board of directors of AnaptysBio, Inc., Bright Peak Therapeutics and Design Therapeutics, all pharmaceutical companies, and as the chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. He also previously served as a member of the board of directors of Poseida Therapeutics, Inc., Xeris Pharmaceuticals, Inc. and Blacksmith Medicines, Inc. (f/k/a Forge Therapeutics, Inc.). Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from 2013 until its sale to Teva Pharmaceuticals, Inc. in 2015. Prior to Auspex Pharmaceuticals, Inc., he co founded Trius Therapeutics, Inc. (formerly Nasdaq:TSRX), where he served as Chief Financial Officer from 2004 until its merger with Cubist Pharmaceuticals, Inc. in 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. Mr. Schmid holds a Bachelor's degree in Economics from Wesleyan University and a Master of Business Administration degree from the University of San Diego.
高管简历
中英对照 | 中文 | 英文- Vipin Garg
Vipin Garg担任公司的首席执行官，2013年10月起担任董事会成员，2014年7月被任命为总裁。在加入公司之前，Garg博士担任Tranzyme股份有限公司（Tranzyme Inc.，现在的Ocera Therapeutics股份有限公司（Ocera Therapeutics, Inc.）NASDAQ： OCRX）的总裁、首席执行官和董事（2001年9月-2013年7月）。Garg博士也担任运营和业务拓展副总裁，随后担任Apex Bioscience股份有限公司（Apex Bioscience, Inc.）的运营总监（1994-2000年）；担任DNX Bio-Therapeutics股份有限公司（DNX Bio-Therapeutics, Inc.）的开发副总裁（1992-1994年）；担任Sepracor股份有限公司（Sepracor, Inc.，现在的Dainippon Sumitomo Pharma）的技术服务和营销董事（1989-1992年）；担任Bio-Response股份有限公司（Bio-Response Inc.）的合同服务经理（1986-1989年）。Garg博士也担任北卡罗来纳生物技术中心（North Carolina Biotechnology Center）董事会成员和CED（前身是创业发展委员会）的执行委员会工作，还是卡罗莱纳地区安永年度企业家奖（Ernst & Young Entrepreneur of the Year Award for the Carolinas Region）获得者。Garg博士拥有澳大利亚阿德雷德大学（University of Adelaide, Australia）生物技术博士学位、印度新德里印度农业研究所（Indian Agricultural Research Institute in New Delhi, India）硕士学位和印度密拉特大学（Meerut University, India）学士学位。
Vipin Garg has served as our Chief Executive Officer and a member of our board of directors since October 2013 and was named our President in July 2014. Prior to joining us, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme, Inc., now Ocera Therapeutics, Inc. NASDAQ: OCRX from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000 as Vice President of Development at DNX Bio-Therapeutics, Inc. from 1992 to 1994 as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992 and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst & Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India.- Vipin Garg担任公司的首席执行官，2013年10月起担任董事会成员，2014年7月被任命为总裁。在加入公司之前，Garg博士担任Tranzyme股份有限公司（Tranzyme Inc.，现在的Ocera Therapeutics股份有限公司（Ocera Therapeutics, Inc.）NASDAQ： OCRX）的总裁、首席执行官和董事（2001年9月-2013年7月）。Garg博士也担任运营和业务拓展副总裁，随后担任Apex Bioscience股份有限公司（Apex Bioscience, Inc.）的运营总监（1994-2000年）；担任DNX Bio-Therapeutics股份有限公司（DNX Bio-Therapeutics, Inc.）的开发副总裁（1992-1994年）；担任Sepracor股份有限公司（Sepracor, Inc.，现在的Dainippon Sumitomo Pharma）的技术服务和营销董事（1989-1992年）；担任Bio-Response股份有限公司（Bio-Response Inc.）的合同服务经理（1986-1989年）。Garg博士也担任北卡罗来纳生物技术中心（North Carolina Biotechnology Center）董事会成员和CED（前身是创业发展委员会）的执行委员会工作，还是卡罗莱纳地区安永年度企业家奖（Ernst & Young Entrepreneur of the Year Award for the Carolinas Region）获得者。Garg博士拥有澳大利亚阿德雷德大学（University of Adelaide, Australia）生物技术博士学位、印度新德里印度农业研究所（Indian Agricultural Research Institute in New Delhi, India）硕士学位和印度密拉特大学（Meerut University, India）学士学位。
- Vipin Garg has served as our Chief Executive Officer and a member of our board of directors since October 2013 and was named our President in July 2014. Prior to joining us, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme, Inc., now Ocera Therapeutics, Inc. NASDAQ: OCRX from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000 as Vice President of Development at DNX Bio-Therapeutics, Inc. from 1992 to 1994 as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992 and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst & Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India.
- Richard Eisenstadt
Richard Eisenstadt于2014年5月至2021年3月期间在Mallinckrodt Pharmaceuticals NYSE：MNK担任首席财务官。Neos治疗公司 Eisenstadt先生于2013年1月至2014年5月期间在Arborgen Inc.担任首席财务官，并于2003年6月至2012年12月期间在Tranzyme，Inc.（现为TERM5 NYSE：MNK的一部分）担任财务副总裁兼首席财务官。他此前曾在Cogent Neuroscience，Inc.和Nimbus CD International，Inc.担任财务领导职务。Eisenstadt先生获得了詹姆斯麦迪逊大学的工商管理硕士学位和北卡罗来纳大学教堂山分校的经济学学士学位。
Richard Eisenstadt served as Chief Financial Officer from May 2014 to March 2021 of Neos Therapeutics, Inc. Mr. Eisenstadt served as Chief Financial Officer of ArborGen Inc. from January 2013 to May 2014 and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc., now part of Mallinckrodt Pharmaceuticals NYSE: MNK from June 2003 to December 2012. He previously held financial leadership positions at Cogent Neuroscience, Inc. and Nimbus CD International, Inc. Mr. Eisenstadt received his M.B.A. from James Madison University and his B.A. in Economics from the University of North Carolina, Chapel Hill.- Richard Eisenstadt于2014年5月至2021年3月期间在Mallinckrodt Pharmaceuticals NYSE：MNK担任首席财务官。Neos治疗公司 Eisenstadt先生于2013年1月至2014年5月期间在Arborgen Inc.担任首席财务官，并于2003年6月至2012年12月期间在Tranzyme，Inc.（现为TERM5 NYSE：MNK的一部分）担任财务副总裁兼首席财务官。他此前曾在Cogent Neuroscience，Inc.和Nimbus CD International，Inc.担任财务领导职务。Eisenstadt先生获得了詹姆斯麦迪逊大学的工商管理硕士学位和北卡罗来纳大学教堂山分校的经济学学士学位。
- Richard Eisenstadt served as Chief Financial Officer from May 2014 to March 2021 of Neos Therapeutics, Inc. Mr. Eisenstadt served as Chief Financial Officer of ArborGen Inc. from January 2013 to May 2014 and as Vice President of Finance and Chief Financial Officer of Tranzyme, Inc., now part of Mallinckrodt Pharmaceuticals NYSE: MNK from June 2003 to December 2012. He previously held financial leadership positions at Cogent Neuroscience, Inc. and Nimbus CD International, Inc. Mr. Eisenstadt received his M.B.A. from James Madison University and his B.A. in Economics from the University of North Carolina, Chapel Hill.
- Thomas McDonnell
Thomas McDonnell自2015年4月起担任公司的商务总监。在加入公司之前，McDonnell先生在Shire NASDAQ：SHPG工作了10年，目前担任美国营销（U.S. Marketing）的神经科学事业部的副总裁（2013年12月-2015年3月）；2012年8月-2013年11月他成为Shire的成人精神病学总经理和副总裁。先前，他在Shire担任几家商业和营销职位，包括Equasym XL的高级董事、总经理和Intuniv的营销高级董事、Vyvanse营销董事和Adderall XR的高级产品经理。1997-2005年他在Abbott Laboratories and Knoll Pharmaceuticals担任不同的销售、销售管理和营销职位。McDonnell先生拥有穆伦堡学院（Muhlenberg College）营销学士学位。
Thomas McDonnell has served as our Chief Commercial Officer since April 2015. Prior to joining us, Mr. McDonnell spent ten years with Shire NASDAQ:SHPG, most recently as Vice President of U.S. Marketing in the Neuroscience Business Unit from December 2013 to March 2015. From August 2012 to November 2013 he was Vice President, General Manager of Adult Psychiatry at Shire. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR. From 1997 to 2005 he held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals. Mr. McDonnell received his B.A. in Marketing from Muhlenberg College.- Thomas McDonnell自2015年4月起担任公司的商务总监。在加入公司之前，McDonnell先生在Shire NASDAQ：SHPG工作了10年，目前担任美国营销（U.S. Marketing）的神经科学事业部的副总裁（2013年12月-2015年3月）；2012年8月-2013年11月他成为Shire的成人精神病学总经理和副总裁。先前，他在Shire担任几家商业和营销职位，包括Equasym XL的高级董事、总经理和Intuniv的营销高级董事、Vyvanse营销董事和Adderall XR的高级产品经理。1997-2005年他在Abbott Laboratories and Knoll Pharmaceuticals担任不同的销售、销售管理和营销职位。McDonnell先生拥有穆伦堡学院（Muhlenberg College）营销学士学位。
- Thomas McDonnell has served as our Chief Commercial Officer since April 2015. Prior to joining us, Mr. McDonnell spent ten years with Shire NASDAQ:SHPG, most recently as Vice President of U.S. Marketing in the Neuroscience Business Unit from December 2013 to March 2015. From August 2012 to November 2013 he was Vice President, General Manager of Adult Psychiatry at Shire. Previously, he held several commercial and marketing positions at Shire, including Senior Director, General Manager for Equasym XL, Senior Director of Marketing for Intuniv, Director of Marketing for Vyvanse, and Senior Product Manager for Adderall XR. From 1997 to 2005 he held various sales, sales management and marketing positions at Abbott Laboratories and Knoll Pharmaceuticals. Mr. McDonnell received his B.A. in Marketing from Muhlenberg College.
- Dorothy Engelking
Dorothy Engelking自2010年4月起担任公司监管事物副总裁。在加入公司之前，Engelking女士担任Kendle International股份有限公司（Kendle International, Inc.）的副总裁（2008年7月-2009年7月）；Xanodyne Pharmaceutics股份有限公司（Xanodyne Pharmaceutics, Inc.）的监管事物高级副总裁（2006年3月-2008年7月）；Watson Pharmaceuticals 股份有限公司（Watson Pharmaceuticals Inc.，现在是Actavis plc NYSE： ACT）监管事物副总裁（1999年1月-2006年3月）。她拥有南他州矿业和技术学校（South Dakota School of Mines and Technology）化学学士学位和分析化学硕士学位，拥有监管事物专业协会（Regulatory Affairs Professional Society）的监管证书。
Dorothy Engelking has served as our Vice President of Regulatory Affairs since April 2010. Prior to joining us, Ms. Engelking served as Vice President of Kendle International, Inc. from July 2008 to July 2009 Senior Vice President of Regulatory Affairs at Xanodyne Pharmaceutics, Inc. from March 2006 to July 2008 and as Vice President of Regulatory Affairs at Watson Pharmaceuticals Inc., now Actavis plc NYSE: ACT from January 1999 to March 2006. Ms. Engelking received her B.S. in Chemistry and M.S. in Analytical Chemistry from South Dakota School of Mines and Technology, and holds a Regulatory Certificate from the Regulatory Affairs Professional Society.- Dorothy Engelking自2010年4月起担任公司监管事物副总裁。在加入公司之前，Engelking女士担任Kendle International股份有限公司（Kendle International, Inc.）的副总裁（2008年7月-2009年7月）；Xanodyne Pharmaceutics股份有限公司（Xanodyne Pharmaceutics, Inc.）的监管事物高级副总裁（2006年3月-2008年7月）；Watson Pharmaceuticals 股份有限公司（Watson Pharmaceuticals Inc.，现在是Actavis plc NYSE： ACT）监管事物副总裁（1999年1月-2006年3月）。她拥有南他州矿业和技术学校（South Dakota School of Mines and Technology）化学学士学位和分析化学硕士学位，拥有监管事物专业协会（Regulatory Affairs Professional Society）的监管证书。
- Dorothy Engelking has served as our Vice President of Regulatory Affairs since April 2010. Prior to joining us, Ms. Engelking served as Vice President of Kendle International, Inc. from July 2008 to July 2009 Senior Vice President of Regulatory Affairs at Xanodyne Pharmaceutics, Inc. from March 2006 to July 2008 and as Vice President of Regulatory Affairs at Watson Pharmaceuticals Inc., now Actavis plc NYSE: ACT from January 1999 to March 2006. Ms. Engelking received her B.S. in Chemistry and M.S. in Analytical Chemistry from South Dakota School of Mines and Technology, and holds a Regulatory Certificate from the Regulatory Affairs Professional Society.
- Juergen A. Martens
Juergen A. Martens， 哲学博士，2005年9月开始就是营运部副总裁和首席科技官。2000年到2005年8月，他被内克塔治疗公司（Nektar Therapeutics）雇佣，是它的制药科技部发展部的副总裁。1998年到2000年，他在喷气精细化学品公司（Aerojet Fine Chemicals）担任科技管理职位。1996年到1998年，他在美国富美实公司（FMC Corporation）的技术管理岗位任职。1987年到1996年，他在瑞士和美国的龙沙集团（Lonza）的研发部，计划管理部和业务进程发展部担任责任越来越大的行政职位。他持有德国曼海姆专科的化学工程技术学士学位。他持有德国马尔堡大学（the University of Marburg）物理化学博士学位和化学学士和硕士学位。
Juergen A. Martens has served as our Chief Technology and Operations Officer since May 2016. Prior to joining us, Dr. Martens served as Chief Operating Officer of MannKind Corporation NASDAQ: MNKD from January 2015 to March 2016 and as their Corporate Vice President of Operations and Chief Technology Officer from September 2005 to January 2015. From 2000 to August 2005 he was employed by Nektar Therapeutics, serving as Vice President of Pharmaceutical Technology Development. Previously, he held technical management positions at Aerojet Fine Chemicals from 1998 to 2000 and at FMC Corporation from 1996 to 1998. From 1987 to 1996 Dr. Martens held a variety of management positions with increased managerial responsibility in R&D, plant management, and business process development at Lonza, in Switzerland and in the United States. Dr. Martens holds a bachelor's degree in chemical engineering from the Technical College Mannheim/Germany, a bachelor's and master's degree in Chemistry and a doctorate in Physical Chemistry from the University of Marburg/Germany. Dr. Martens obtained an executive master's degree in Management (EMTM) from the University of Pennsylvania, a joint program of the Wharton School of Business & the School of Engineering and Applied Science.- Juergen A. Martens， 哲学博士，2005年9月开始就是营运部副总裁和首席科技官。2000年到2005年8月，他被内克塔治疗公司（Nektar Therapeutics）雇佣，是它的制药科技部发展部的副总裁。1998年到2000年，他在喷气精细化学品公司（Aerojet Fine Chemicals）担任科技管理职位。1996年到1998年，他在美国富美实公司（FMC Corporation）的技术管理岗位任职。1987年到1996年，他在瑞士和美国的龙沙集团（Lonza）的研发部，计划管理部和业务进程发展部担任责任越来越大的行政职位。他持有德国曼海姆专科的化学工程技术学士学位。他持有德国马尔堡大学（the University of Marburg）物理化学博士学位和化学学士和硕士学位。
- Juergen A. Martens has served as our Chief Technology and Operations Officer since May 2016. Prior to joining us, Dr. Martens served as Chief Operating Officer of MannKind Corporation NASDAQ: MNKD from January 2015 to March 2016 and as their Corporate Vice President of Operations and Chief Technology Officer from September 2005 to January 2015. From 2000 to August 2005 he was employed by Nektar Therapeutics, serving as Vice President of Pharmaceutical Technology Development. Previously, he held technical management positions at Aerojet Fine Chemicals from 1998 to 2000 and at FMC Corporation from 1996 to 1998. From 1987 to 1996 Dr. Martens held a variety of management positions with increased managerial responsibility in R&D, plant management, and business process development at Lonza, in Switzerland and in the United States. Dr. Martens holds a bachelor's degree in chemical engineering from the Technical College Mannheim/Germany, a bachelor's and master's degree in Chemistry and a doctorate in Physical Chemistry from the University of Marburg/Germany. Dr. Martens obtained an executive master's degree in Management (EMTM) from the University of Pennsylvania, a joint program of the Wharton School of Business & the School of Engineering and Applied Science.